32 / 34
Tumor angiogenesis is a continuously evolving process.
Biological determinants that are significant during first-line may lose their
role in favor of different ones across subsequent lines of treatment.
It is expected that early switch to alternative antiangiogenic agent based on
circulating cytokines and angiogenic factors (CAFs) will maximize treatment
benefit and improve patient outcome.
Conclusions